The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Average glucose values based on continuous glucose monitoring
Timeframe: 3 months
Estimated average glucose (eAG) values based on hemoglobin-A1c lab values
Timeframe: 3 months
Estimated average glucose (eAG) values based on fructosamine lab values
Timeframe: 3 months